Congratulations to our French colleagues for being cited as ‘firme à l’honneur’ – company on the honors list – by Prescrire, a non-profit continuing education organization, committed to better patient care. AMOMED France received this award for Rapibloc® thanks to the transparency of medical information provided by Medical Director France & Head of Strategic Business Development and Technology Transfer Olivier Bouvet. Out of 86 pharma companies that were screened only seven received an award for transparency of information.
Every January, the organization hosts the “Pilule d’Or” (Golden Pill) ceremony during which awards for drugs, drug packaging and information are presented to pharmaceutical companies. Benoit Gredelu, Country Manager for AMOMED France, accepted the award at the event held in Paris on January 31, 2019.
What is Prescrire?
Prescrire‘s purpose is to work independently, in favor of quality healthcare, first and foremost in the interest of patients. Prescrire, which is entirely subscriber financed, provides healthcare professionals – and consequently patients – with the clear, comprehensive and reliable information they need about drugs and therapeutic & diagnostic strategies. Prescrire aims to offer help in distinguishing between the wealth of new products on the market, which might be useful for therapies and provide information about new indications.
Prescrire does not accept any advertising, grants or outside support and is therefore fully independent from industry interests.
What are the Information Awards?
For Prescrire, the responsibility to share information about drugs with the public lies with the pharmaceutical companies. This information helps ensure the appropriate use of the product, consequently protecting patients from adverse effects. As part of the award process, Prescrire looks at clinical data, packaging, regulatory and administrative documentation. The award reflects how companies assume their responsibilities to make this information available.
AMOMED France provided detailed and relevant information upon Prescrire’s request and was rewarded for this transparency.
We are very honored!